• KalVista Pharmaceuticals recently reported interim results from its KONFIDENT-KID trial, showing EKTERLY (sebetralstat) delivered rapid, well-tolerated oral treatment for hereditary angioedema attacks in children aged 2–11, with no serious or treatment-related adverse events.
• The trial, now the largest pediatric hereditary angioedema study and completed enrollment a year early, highlights strong clinical interest in a first-in-class oral option for a population currently limited to burdensome intravenous on-demand therapy.
• We’ll now examine how KONFIDENT-KID’s early completion and supportive interim data might influence KalVista’s investment narrative around EKTERLY’s growth.

Outshine the giants: these 21 early-stage AI stocks could fund your retirement.

KalVista Pharmaceuticals Investment Narrative Recap

To own KalVista, you need to believe EKTERLY can become a core oral treatment across hereditary angioedema, broad enough to eventually support profitability despite today’s losses and high commercialization spend. The KONFIDENT KID interim data support EKTERLY’s clinical profile and strengthen the near term pediatric NDA catalyst, while also underscoring the key risk that broader, lower burden use could lead to less frequent refills and more normal attack patterns than early high burden adopters.

Among recent announcements, the earlier FDA approval and launches of EKTERLY for patients aged 12 and older in the US and Europe are most relevant, because they establish the commercial and payer groundwork that any pediatric label expansion would enter into. Together with KONFIDENT S data in adults and adolescents, this creates a more complete backdrop for assessing how pediatric results could affect long term utilization, refill behavior and the company’s path toward earnings leverage.

Yet, even as pediatric data look encouraging, tighter future payer policies and a reset in refill volumes remain risks investors should be aware of...

KalVista Pharmaceuticals' narrative projects $297.2 million revenue and $10.7 million earnings by 2029. This requires 492.9% yearly revenue growth and a $213.8 million earnings increase from $-203.1 million today.

Uncover how KalVista Pharmaceuticals' forecasts yield a $31.00 fair value, a 60% upside to its current price.

Exploring Other Perspectives

Some of the most optimistic analysts were already assuming revenue could reach about US$750 million by 2028 and earnings turn positive, which is much more aggressive than consensus and highlights how views on EKTERLY’s long term adoption, especially if pediatric use proves broader or more limited than expected, can differ sharply among investors.

Explore 6 other fair value estimates on KalVista Pharmaceuticals - why the stock might be worth less than half the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your KalVista Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free KalVista Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate KalVista Pharmaceuticals' overall financial health at a glance.

Ready For A Different Approach?

Opportunities like this don't last. These are today's most promising picks. Check them out now:

• We've uncovered the 11 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.
• Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• The latest GPUs need a type of rare earth metal called Terbium and there are only 27 companies in the world exploring or producing it. Find the list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.